All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Dose adjustments are commonplace in the treatment of multiple myeloma (MM), particularly in the older and frail population who are less able to tolerate toxicities. Clinical trial data from the OPTIMISMM trial (NCT01734928) provided evidence for the use of pomalidomide, bortezomib, and dexamethasone (PVd) in the treatment of relapsed/refractory MM. However, there is a lack of understanding of the outcomes of this combination in patients who are frail or require a dose adjustment.1
Here, we summarize a subanalysis by Oriol et al. published in Clinical Lymphoma, Myeloma and Leukemia on results from the OPTIMISMM trial by frailty status and bortezomib dose adjustment.
The Multiple Myeloma Hub has previously covered the overall results from OPTIMISMM here.
Figure 1. Response data by frailty status and bortezomib dose adjustment*
CI, confidence interval; CR, complete response; NE, not evaluable; OR, odds ratio; ORR, overall response date; PD, progressive disease; PR, partial response; sCR, stringent CR; SD, stable disease; VGPR, very good PR.
*Data from Oriol, et al.1
Key learnings1 |
---|
|
Subscribe to get the best content related to multiple myeloma delivered to your inbox